Recent news primarily covers earnings call transcripts of various companies and includes specific updates on Mountain Crest Acquisition Corp. V's Nasdaq compliance and business combination activities.

• Mountain Crest Acquisition Corp. V received a notification of deficiency from Nasdaq related to delayed filing of quarterly reports on Form 10-Q and is making progress towards regaining compliance [N1].
• MCAG announced a business combination agreement with CUBEBIO Co., Ltd. to become publicly listed [N1].
• The company has transferred its listing to the Nasdaq Capital Market, maintaining its trading symbols MCAG, MCAGU, and MCAGR [N1].

Mountain Crest Acquisition Corp. V has demonstrated the ability to engage in business combination agreements with innovative companies such as AUM Biosciences and CUBEBIO Co., Ltd., indicating access to promising targets in the biotech and diagnostic sectors. The management team's extensive experience in SPACs and public markets supports disciplined deal sourcing and execution. The company has taken steps to address Nasdaq listing compliance issues, maintaining its public listing and access to capital markets. The trust account funds and working capital loans provide financial resources to support transaction costs and working capital needs. The focus on companies with underappreciated assets and growth opportunities in North America and Asia Pacific regions aligns with market demand for innovative healthcare and technology solutions.

The company has faced multiple Nasdaq listing compliance challenges related to market value of listed securities, publicly held shares, and timely SEC filings, which could pose risks to its continued listing and ability to complete a business combination. The termination of the initial business combination agreement with AUM Biosciences indicates execution risk in completing transactions. Liquidity outside the trust account is limited, with a current ratio of 0.02 as of June 30, 2026, which may constrain operational flexibility. The success of the company depends on identifying and consummating a suitable business combination within the extended combination period, which remains uncertain. Market volatility and geopolitical risks may also impact the ability to complete a transaction or the performance of the combined entity.

As a special purpose acquisition company, Mountain Crest Acquisition Corp. V's moat is primarily derived from its management team's experience and network in identifying and executing business combinations with target companies that have underappreciated assets or growth potential. The company leverages its relationships with venture capitalists, private equity, hedge funds, and industry experts to source acquisition opportunities. The SPAC structure provides access to public capital markets for private companies seeking to go public, which can be a competitive advantage in deal sourcing and execution. However, the moat is contingent on successful identification and completion of a business combination and the subsequent performance of the combined entity.

• Nasdaq Listing Compliance Risk: The company has received multiple deficiency notices from Nasdaq related to market value and timely SEC filings, requiring plans to regain compliance. Failure to maintain listing standards could lead to delisting and loss of access to public capital markets.
• Business Combination Execution Risk: The termination of the business combination agreement with AUM Biosciences and the need to complete a new combination with CUBEBIO Co., Ltd. highlight risks in successfully identifying and closing a transaction within the allowed timeframe.
• Liquidity Risk: As of June 30, 2026, the company has limited liquidity outside of its trust account, with a current ratio of 0.02 and cash ratio of 0.2, which may limit its ability to fund operations and transaction costs without additional financing.
• Geopolitical and Market Volatility Risk: Ongoing geopolitical conflicts and market volatility may adversely affect the company's ability to find suitable targets, raise financing, or complete a business combination on acceptable terms.

• Mountain Crest Acquisition Corp. V (MCAG) is a blank check company formed under Delaware law on April 8, 2021, for the purpose of effecting a business combination with one or more businesses, referred to as the initial business combination [S1].
• The company intends to pursue targets primarily in North America and Asia Pacific regions, excluding China, and had a restriction against business combinations with companies principally operating in China, which was later removed by stockholder approval [S1].
• MCAG completed its initial public offering in November 2021, selling 6,900,000 units at $10.00 per unit [S1].
• The company has not engaged in any operations or generated revenues to date; its activities have been organizational and preparatory for a business combination [S5].
• MCAG entered into a business combination agreement with AUM Biosciences Pte. Ltd. in October 2022, which was subsequently terminated in June 2023 [S1].
• Following termination of the AUM Biosciences deal, MCAG announced a non-binding term sheet and later a definitive agreement with CUBEBIO Co., Ltd., a Korea-based in-vitro diagnostic company focused on early cancer detection via urine metabolite analysis, aiming to become publicly listed through MCAG [S6, S8].
• The company has experienced Nasdaq listing compliance challenges related to market value of listed securities, publicly held shares, and timely SEC filings, but has taken steps including transferring listing to Nasdaq Capital Market and submitting plans to regain compliance [S1].
• MCAG has issued unsecured promissory notes to its Sponsor and vendors to finance working capital and transaction costs, some of which have been converted into common stock [S1, S22].
• As of June 30, 2026, MCAG reported current assets of $34,315 and current liabilities of $1,777,545, resulting in a current ratio of 0.02 and a cash ratio of 0.2, indicating limited liquidity outside of trust account funds [S2].
• The company held cash and equivalents of $347,243 as of March 31, 2022, and investments held in trust account of $840,639 as of December 31, 2025, which are intended to be used to complete the business combination [S2, S16].
• MCAG's net income was $5,178 for the quarter ended June 30, 2026, with no revenue reported, reflecting limited operating activity [S2].
• The company’s management and board have extensive experience in SPACs and public company operations, led by Dr. Suying Liu who serves as Chairman, CEO, and CFO [S6].
• MCAG’s business model is to identify and acquire a target company with underappreciated assets or growth opportunities, leveraging its network and expertise to create value post-combination [S1, S18].
• The company’s financial statements show accumulated deficits and liabilities including deferred underwriting fees and promissory notes, reflecting costs associated with SPAC operations and preparation for business combination [S8, S15].
• MCAG has received notifications from Nasdaq regarding deficiencies in timely filing of SEC reports but has submitted plans and regained compliance as of late 2024 [S1].